On January 26, 2026, trading occurred on the floor of the New York Stock Exchange (NYSE) in New York City.
Jan 27 – Shares of U.S. health insurance companies experienced a decline on Tuesday following a surprising proposal by the Trump administration for a significant increase in Medicare Advantage rates for 2027, which could potentially erase around $80 billion in market capitalization.
United Health saw its stock plummet almost 20%, marking its largest single-day drop since April of the previous year, influenced also by unexpected sales figures from 2026.
CVS and Humana stocks followed suit, falling approximately 11% and nearly 19%, respectively.
The Centers for Medicare and Medicaid Services expressed on Monday that all three companies—United Health, CVS, and Humana—have considerable exposure to Medicare Advantage, where payment rates are set to rise by a mere 0.09% in 2027, falling well short of the 6% increase analysts anticipated.
Other insurance firms, such as Molina Health and Centene, also saw decreases ranging between 5% and 11%.
Analysts have cautioned that the near-zero updates would pose challenges for insurers already struggling with high medical costs. Baird analyst Michael Herr pointed out that interest rates likely won’t suffice to counter rising costs, implying cuts to benefits or plan withdrawals may become necessary to manage margins in 2027.
The government stated that the proposal reflects underlying cost trends as well as quality assessments from 2026, along with adjustments aimed at compensating providers for treating critically ill patients.
Concerns Over Potential Cuts to Benefits
Some analysts believe this proposal intensifies risks to Medicare Advantage’s profitability and underscores regulatory uncertainty as a short-term challenge for insurance stocks.
Bernstein analyst Lance Wilkes noted that if interest rates stay low, membership growth will likely falter as Medicare plans may need to reduce benefits to bolster margins.
Typically, Medicare Advantage rates are set in early April.
Interestingly, Whit Mayo from Leerink remarked that usual updates tend to be more favorable, suggesting that the timing of this announcement aligns suspiciously with UnitedHealth’s recent financial disclosures.
Although the sector leader posted fourth-quarter results that slightly exceeded Wall Street estimates, it warned of a revenue decline in 2026.
